dsm-firmenich achieves regulatory clearance in China for two HMO ingredients

Date: 10.10.2023Source: dsm-firmenich

dsm-firmenich announced that two of its human milk oligosaccharide (HMO) ingredients have been approved as fortifiers for infant nutrition in China. This approval is a significant milestone as it will create new opportunities for innovation in the field of early life nutrition and make the unique benefits of HMOs accessible to infants and young children in China.

The two HMOs that received approval in China include GlyCare 2′-fucosyllactose (2′-FL), the most prevalent HMO in human breast milk, and GlyCare lacto-N-neotetraose (LNnT), a complex sugar in human milk that is biologically relevant in the early development of the infant gut flora. The 2′-FL HMO has been approved for use in four food categories, including: infant formula, formula for elder infants and young children, infant formula for special medical purposes, and formulated milk powder at a usage level between 0.7-2.4 g/L. LNnT is available for the same applications at 0.2-0.6 g/L.

Roland Sossna / IDM

Print article (with images) Print article (without images)


Always stay up to date and sign up for our newsletter service: